Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Antimuscarinic with atropine-like effects. Indicated in the treatment of overactive bladder. Oral administration once or twice a day.
At the date of the last update, we did not find any published data on its excretion in breast milk.
Its large volume of distribution makes its passage to breast milk in a clinically significant amount unlikely.
Its low oral bioavailability (even lower if taken with food) hinders the transition to plasma of the infant from ingested breast milk, except in the premature and in the immediate neonatal period in which there may be greater intestinal permeability.
Milk production should be monitored, as there are reports (albeit few and old) that anticholinergics can reduce prolactin levels. (Masala 1982).